title: Treating Sjögren's Syndrome: Insights for the Clinician.
abstract: Sjögren's syndrome (SS) is a systemic autoimmune disease that affects the exocrine glands, mainly the salivary and lachrymal glands, with consequent persistent dryness of the mouth and eyes. In addition to the clinical manifestations related to the exocrine gland involvement, a consistent prevalence of patients may present systemic manifestations. Some of these can be ascribed to the periepithelial extension of lymphocytic infiltration whilst others are determined by an immunomediated process affecting small- or medium-size vessels. While the use of tear and saliva substitutes and local or systemic stimulation of residual secretions represent the mainstays of the therapy of sicca component, different immunomodulating or immunosuppressive agents are usually required to treat extraglandular features, similarly to what happens in other connective tissue diseases. In the last few years, the advancement in the understanding the pathogenetic mechanisms of this disorder and the availability of new biologic target therapies seem to offer completely new therapeutic options. The use of B cell depleting or modulating therapies has achieved promising results.
authors.affiliation: Department of Internal Medicine and Section of Rheumatology, 'Villamarina' Hospital, Piombino, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Vitali
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Palombi
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Cataleta